Register for updates about Emgality

Learn more about Emgality when you register with us. Please enter your information below.

You are now registering to receive information about Emgality intended only for healthcare providers. By submitting the information requested below, you certify that you are a healthcare provider. Lilly’s intent is to only provide information to healthcare providers.

Which of Emgality’s indications would you like information about?


IMPORTANT

The information you provide in this form will be used in accordance with the Lilly Privacy Statement. The information you provide to Lilly may also be used for marketing purposes. Also, any information or suggestions you provide regarding the content of any Lilly website, published document, or product will be handled in accordance with our Copyright Statement. By submitting this registration form, I agree that my use of this website and any emails I receive in response to this registration is subject to this website’s Terms of Use, Privacy Statement, and Copyright Policy. I have read the Terms of Use, Privacy Statement, and Copyright Policy. I have read the Terms of Use, Privacy Statement, and Copyright Policy contained on this website and agree to be bound by such terms.


Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019